Acta Neuropathologica

, Volume 121, Issue 1, pp 39–57 | Cite as

Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy

  • Gabor G. Kovacs
  • Jérémie Seguin
  • Isabelle Quadrio
  • Romana Höftberger
  • István Kapás
  • Nathalie Streichenberger
  • Anne Gaëlle Biacabe
  • David Meyronet
  • Raf Sciot
  • Rik Vandenberghe
  • Katalin Majtenyi
  • Lajos László
  • Thomas Ströbel
  • Herbert Budka
  • Armand Perret-Liaudet
Original Paper


The E200K mutation is the most frequent prion protein gene (PRNP) mutation detected worldwide that is associated with Creutzfeldt-Jakob disease (CJD) and thought to have overlapping features with sporadic CJD, yet detailed neuropathological studies have not been reported. In addition to the prion protein, deposition of tau, α-synuclein, and amyloid-β has been reported in human prion disease. To describe the salient and concomitant neuropathological alterations, we performed a systematic clinical, neuropathological, and biochemical study of 39 individuals carrying the E200K PRNP mutation originating from different European countries. The most frequent clinical symptoms were dementia and ataxia followed by myoclonus and various combinations of further symptoms, including vertical gaze palsy and polyneuropathy. Neuropathological examination revealed relatively uniform anatomical pattern of tissue lesioning, predominating in the basal ganglia and thalamus, and also substantia nigra, while the deposition of disease-associated PrP was more influenced by the codon 129 constellation, including different or mixed types of PrPres detected by immunoblotting. Unique and prominent intraneuronal PrP deposition involving brainstem nuclei was also noted. Systematic examination of protein depositions revealed parenchymal amyloid-β in 53.8%, amyloid angiopathy (Aβ) in 23.1%, phospho-tau immunoreactive neuritic profiles in 92.3%, neurofibrillary degeneration in 38.4%, new types of tau pathology in 33.3%, and Lewy-type α-synuclein pathology in 15.4%. TDP-43 and FUS immunoreactive protein deposits were not observed. This is the first demonstration of intensified and combined neurodegeneration in a genetic prion disease due to a single point mutation, which might become an important model to decipher the molecular interplay between neurodegeneration-associated proteins.


Alpha-synuclein Amyloid-beta Prion protein Tau Neurodegeneration 



This study was performed in the frame of the EU FP6 Project Neuroscreen LSHB-CZ-2006-037719 contract No. 037719. We are grateful for the technical assistance of Irene Leisser, Gerda Ricken, Lenkeine Marianna, Katalin Ress, Rachel Plantier, Françoise Didier, and for the kind cooperation of collegues and families of patients supporting our Surveillance systems. RV is a senior clinical investigator of the Research Foundation-Flanders. LL was supported by a grant of the Hungarian Scientific Research Fund (OTKA-NK78012).

Conflict of interest statement


Supplementary material

401_2010_713_MOESM1_ESM.tif (7.7 mb)
Supplementary Figure 1. Detailed anatomical mapping of lesions scores and anatomical correlations of PrP immunoreactivities in different subgroups of patients with E200K genetic CJD. a. Regional distribution of mean scores (+ standard error) of spongiform change and neuronal loss/gliosis in E200K genetic CJD cases grouped according to the codon 129 polymorphism. Summarized results of regions (cortical, hippocampal, basal ganglia and thalamus, brainstem and cerebellum) are indicated with bars. b. Graphic representation of regional differences of PrP immunoreactive patterns in E200K genetic CJD cases with MM or MV at codon 129. Cortical regions are represented as 100% and other regions are compared to the value of the cortical region to show whether their involvement is more or less prominent as in cortical areas (for details of regions see a). c. Mean (+ standard error) scores of intraneuronal PrP immunoreactivity in different anatomical regions in cases showing this pattern. (TIFF 7847 kb)


  1. 1.
    Antoine JC, Laplanche JL, Mosnier JF, Beaudry P, Chatelain J, Michel D (1996) Demyelinating peripheral neuropathy with Creutzfeldt-Jakob disease and mutation at codon 200 of the prion protein gene. Neurology 46:1123–1127PubMedGoogle Scholar
  2. 2.
    Bertoni JM, Brown P, Goldfarb LG, Rubenstein R, Gajdusek DC (1992) Familial Creutzfeldt-Jakob disease (codon 200 mutation) with supranuclear palsy. JAMA 268:2413–2415CrossRefPubMedGoogle Scholar
  3. 3.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMedGoogle Scholar
  4. 4.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMedGoogle Scholar
  5. 5.
    Brown P, Galvez S, Goldfarb LG, Nieto A, Cartier L, Gibbs CJ Jr, Gajdusek DC (1992) Familial Creutzfeldt-Jakob disease in Chile is associated with the codon 200 mutation of the PRNP amyloid precursor gene on chromosome 20. J Neurol Sci 112:65–67CrossRefPubMedGoogle Scholar
  6. 6.
    Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5–22CrossRefPubMedGoogle Scholar
  7. 7.
    Cardone F, Liu QG, Petraroli R, Ladogana A, D’Alessandro M, Arpino C, Di Bari M, Macchi G, Pocchiari M (1999) Prion protein glycotype analysis in familial and sporadic Creutzfeldt-Jakob disease patients. Brain Res Bull 49:429–433CrossRefPubMedGoogle Scholar
  8. 8.
    Chapman J, Arlazoroff A, Goldfarb LG, Cervenakova L, Neufeld MY, Werber E, Herbert M, Brown P, Gajdusek DC, Korczyn AD (1996) Fatal insomnia in a case of familial Creutzfeldt-Jakob disease with the codon 200 (Lys) mutation. Neurology 46:758–761PubMedGoogle Scholar
  9. 9.
    Collinge J, Palmer MS, Campbell T, Sidle KC, Carroll D, Harding A (1993) Inherited prion disease (PrP lysine 200) in Britain: two case reports. BMJ 306:301–302CrossRefPubMedGoogle Scholar
  10. 10.
    de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A (2003) Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29:288–302CrossRefPubMedGoogle Scholar
  11. 11.
    Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5:347–354CrossRefPubMedGoogle Scholar
  12. 12.
    DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65:1074–1080CrossRefPubMedGoogle Scholar
  13. 13.
    Du HN, Li HT, Zhang F, Lin XJ, Shi JH, Shi YH, Ji LN, Hu J, Lin DH, Hu HY (2006) Acceleration of alpha-synuclein aggregation by homologous peptides. FEBS Lett 580:3657–3664CrossRefPubMedGoogle Scholar
  14. 14.
    Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, Budka H, Carmona M, Giaccone G, Krebs B, Limido L, Parchi P, Puig B, Strammiello R, Strobel T, Kretzschmar H (2007) Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 66:35–46CrossRefPubMedGoogle Scholar
  15. 15.
    Fulbright RK, Hoffmann C, Lee H, Pozamantir A, Chapman J, Prohovnik I (2008) MR imaging of familial Creutzfeldt-Jakob disease: a blinded and controlled study. AJNR Am J Neuroradiol 29:1638–1643CrossRefPubMedGoogle Scholar
  16. 16.
    Gelpi E, Heinzl H, Hoftberger R, Unterberger U, Strobel T, Voigtlander T, Drobna E, Jarius C, Lang S, Waldhor T, Bernheimer H, Budka H (2008) Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study. Neuroepidemiology 30:215–221CrossRefPubMedGoogle Scholar
  17. 17.
    Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K, Prelli F, Farlow MR, Dlouhy SR, Tagliavini F (1996) Prion protein amyloidosis. Brain Pathol 6:127–145CrossRefPubMedGoogle Scholar
  18. 18.
    Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P, Morris JC (2009) Codistribution of amyloid beta plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K–129M haplotype. Arch Neurol 66:1240–1246CrossRefPubMedGoogle Scholar
  19. 19.
    Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ, Haik S, Fociani P, Bugiani O, Tagliavini F (2008) Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiol Aging 29:1864–1873CrossRefPubMedGoogle Scholar
  20. 20.
    Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer’s disease: identification of phosphorylation sites in tau protein. Biochem J 301(Pt 3):871–877PubMedGoogle Scholar
  21. 21.
    Goldfarb LG, Brown P, Mitrova E, Cervenakova L, Goldin L, Korczyn AD, Chapman J, Galvez S, Cartier L, Rubenstein R et al (1991) Creutzfeldt-Jacob disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families. Eur J Epidemiol 7:477–486CrossRefPubMedGoogle Scholar
  22. 22.
    Goldfarb LG, Mitrova E, Brown P, Toh BK, Gajdusek DC (1990) Mutation in codon 200 of scrapie amyloid protein gene in two clusters of Creutzfeldt-Jakob disease in Slovakia. Lancet 336:514–515CrossRefPubMedGoogle Scholar
  23. 23.
    Gossrau G, Herting B, Mockel S, Kempe A, Koch R, Reichmann H, Lampe JB (2006) Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson’s disease. J Neural Transm 113:331–337CrossRefPubMedGoogle Scholar
  24. 24.
    Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging 28:327–335CrossRefPubMedGoogle Scholar
  25. 25.
    Haik S, Privat N, Adjou KT, Sazdovitch V, Dormont D, Duyckaerts C, Hauw JJ (2002) Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol 103:516–520CrossRefPubMedGoogle Scholar
  26. 26.
    Hainfellner JA, Parchi P, Kitamoto T, Jarius C, Gambetti P, Budka H (1999) A novel phenotype in familial Creutzfeldt-Jakob disease: prion protein gene E200K mutation coupled with valine at codon 129 and type 2 protease-resistant prion protein. Ann Neurol 45:812–816CrossRefPubMedGoogle Scholar
  27. 27.
    Hill AF, Joiner S, Beck JA, Campbell TA, Dickinson A, Poulter M, Wadsworth JD, Collinge J (2006) Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 129:676–685CrossRefPubMedGoogle Scholar
  28. 28.
    Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, Richter-Landsberg C, Lee VM, Trojanowski JQ (2003) Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 163:1021–1031PubMedGoogle Scholar
  29. 29.
    Hsiao K, Meiner Z, Kahana E, Cass C, Kahana I, Avrahami D, Scarlato G, Abramsky O, Prusiner SB, Gabizon R (1991) Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med 324:1091–1097CrossRefPubMedGoogle Scholar
  30. 30.
    Inoue I, Kitamoto T, Doh-ura K, Shii H, Goto I, Tateishi J (1994) Japanese family with Creutzfeldt-Jakob disease with codon 200 point mutation of the prion protein gene. Neurology 44:299–301PubMedGoogle Scholar
  31. 31.
    Isaacs AM, Powell C, Webb TE, Linehan JM, Collinge J, Brandner S (2008) Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. Neuropathol Appl Neurobiol 34:446–456CrossRefPubMedGoogle Scholar
  32. 32.
    Jarius C, Kovacs GG, Belay G, Hainfellner JA, Mitrova E, Budka H (2003) Distinctive cerebellar immunoreactivity for the prion protein in familial (E200K) Creutzfeldt-Jakob disease. Acta Neuropathol 105:449–454PubMedGoogle Scholar
  33. 33.
    Korczyn AD, Chapman J, Goldfarb LG, Brown P, Gajdusek DC (1991) A mutation in the prion protein gene in Creutzfeldt-Jakob disease in Jewish patients of Libyan, Greek, and Tunisian origin. Ann NY Acad Sci 640:171–176PubMedGoogle Scholar
  34. 34.
    Kosik KS, Orecchio LD, Binder L, Trojanowski JQ, Lee VM, Lee G (1988) Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1:817–825CrossRefPubMedGoogle Scholar
  35. 35.
    Kovacs GG, Bakos A, Mitrova E, Minarovits J, Laszlo L, Majtenyi K (2007) Human prion diseases: the Hungarian experience. Ideggyogy Sz 60:447–452PubMedGoogle Scholar
  36. 36.
    Kovacs GG, Botond G, Budka H (2010) Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol 119:389–408CrossRefPubMedGoogle Scholar
  37. 37.
    Kovacs GG, Budka H (2009) Molecular pathology of human prion diseases. Int J Mol Sci 10:976–999CrossRefPubMedGoogle Scholar
  38. 38.
    Kovacs GG, Gelpi E, Strobel T, Ricken G, Nyengaard JR, Bernheimer H, Budka H (2007) Involvement of the endosomal-lysosomal system correlates with regional pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 66:628–636CrossRefPubMedGoogle Scholar
  39. 39.
    Kovacs GG, Horvath S, Strobel T, Puskas M, Bakos A, Summers DM, Will RG, Budka H (2009) Genetic Creutzfeldt-Jakob disease mimicking variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 80:1410–1411CrossRefPubMedGoogle Scholar
  40. 40.
    Kovacs GG, Laszlo L, Bakos A, Minarovits J, Bishop MT, Strobel T, Vajna B, Mitrova E, Majtenyi K (2005) Increased incidence of genetic human prion disease in Hungary. Neurology 65:1666–1669CrossRefPubMedGoogle Scholar
  41. 41.
    Kovacs GG, Puopolo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, Collins SJ, Boyd A, Giulivi A, Coulthart M, Delasnerie-Laupretre N, Brandel JP, Zerr I, Kretzschmar HA, de Pedro-Cuesta J, Calero-Lara M, Glatzel M, Aguzzi A, Bishop M, Knight R, Belay G, Will R, Mitrova E (2005) Genetic prion disease: the EUROCJD experience. Hum Genet 118:166–174CrossRefPubMedGoogle Scholar
  42. 42.
    Kovacs GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RS, Budka H (2002) Mutations of the prion protein gene phenotypic spectrum. J Neurol 249:1567–1582CrossRefPubMedGoogle Scholar
  43. 43.
    Kovacs GG, Voigtlander T, Hainfellner JA, Budka H (2002) Distribution of intraneuronal immunoreactivity for the prion protein in human prion diseases. Acta Neuropathol 104:320–326PubMedGoogle Scholar
  44. 44.
    Lee HS, Sambuughin N, Cervenakova L, Chapman J, Pocchiari M, Litvak S, Qi HY, Budka H, del Ser T, Furukawa H, Brown P, Gajdusek DC, Long JC, Korczyn AD, Goldfarb LG (1999) Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease. Am J Hum Genet 64:1063–1070CrossRefPubMedGoogle Scholar
  45. 45.
    Mancuso M, Siciliano G, Capellari S, Orsucci D, Moretti P, Di Fede G, Suardi S, Strammiello R, Parchi P, Tagliavini F, Murri L (2009) Creutzfeldt-Jakob disease with E200K PRNP mutation: a case report and revision of the literature. Neurol Sci 30:417–420CrossRefPubMedGoogle Scholar
  46. 46.
    Mead S, Webb TE, Campbell TA, Beck J, Linehan JM, Rutherfoord S, Joiner S, Wadsworth JD, Heckmann J, Wroe S, Doey L, King A, Collinge J (2007) Inherited prion disease with 5-OPRI: phenotype modification by repeat length and codon 129. Neurology 69:730–738CrossRefPubMedGoogle Scholar
  47. 47.
    Meiner Z, Gabizon R, Prusiner SB (1997) Familial Creutzfeldt-Jakob disease. Codon 200 prion disease in Libyan Jews. Medicine (Baltimore) 76:227–237CrossRefGoogle Scholar
  48. 48.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedGoogle Scholar
  49. 49.
    Mitrova E, Belay G (2002) Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development. Acta Virol 46:31–39PubMedGoogle Scholar
  50. 50.
    Neufeld MY, Josiphov J, Korczyn AD (1992) Demyelinating peripheral neuropathy in Creutzfeldt-Jakob disease. Muscle Nerve 15:1234–1239CrossRefPubMedGoogle Scholar
  51. 51.
    Nixon R, Camicioli R, Cervenakova L, Mastrianni J (2000) The PRNP-V180I mutation is associated with abnormally glycosylated PrPCJD and intracellular PrP accumulations. In: XIVth International Congress of Neuropathology Brain Pathol Birmingham, UK, p 670Google Scholar
  52. 52.
    Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 131:1969–1978CrossRefPubMedGoogle Scholar
  53. 53.
    Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233CrossRefPubMedGoogle Scholar
  54. 54.
    Parchi P, Strammiello R, Notari S, Giese A, Langeveld JP, Ladogana A, Zerr I, Roncaroli F, Cras P, Ghetti B, Pocchiari M, Kretzschmar H, Capellari S (2009) Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 118:659–671CrossRefPubMedGoogle Scholar
  55. 55.
    Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HN, Turner AJ, Hooper NM (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. Proc Natl Acad Sci USA 104:11062–11067CrossRefPubMedGoogle Scholar
  56. 56.
    Peoc’h K, Manivet P, Beaudry P, Attane F, Besson G, Hannequin D, Delasnerie-Laupretre N, Laplanche JL (2000) Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Hum Mutat 15:482CrossRefPubMedGoogle Scholar
  57. 57.
    Puoti G, Rossi G, Giaccone G, Awan T, Lievens PM, Defanti CA, Tagliavini F, Bugiani O (2000) Polymorphism at codon 129 of PRNP affects the phenotypic expression of Creutzfeldt-Jakob disease linked to E200K mutation. Ann Neurol 48:269–270CrossRefPubMedGoogle Scholar
  58. 58.
    Quadrio I, Ugnon-Cafe S, Dupin M, Esposito G, Streichenberger N, Krolak-Salmon P, Vital A, Pellissier JF, Perret-Liaudet A, Perron H (2009) Rapid diagnosis of human prion disease using streptomycin with tonsil and brain tissues. Lab Invest 89:406–413CrossRefPubMedGoogle Scholar
  59. 59.
    Roeber S, Krebs B, Neumann M, Windl O, Zerr I, Grasbon-Frodl EM, Kretzschmar HA (2005) Creutzfeldt-Jakob disease in a patient with an R208H mutation of the prion protein gene (PRNP) and a 17-kDa prion protein fragment. Acta Neuropathol 109:443–448CrossRefPubMedGoogle Scholar
  60. 60.
    Santpere G, Puig B, Ferrer I (2006) Low molecular weight species of tau in Alzheimer’s disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing. Neurosci Lett 399:106–110CrossRefPubMedGoogle Scholar
  61. 61.
    Scholz SW, Xiromerisiou G, Fung HC, Eerola J, Hellstrom O, Papadimitriou A, Hadjigeorgiou GM, Tienari PJ, Fernandez HH, Mandel R, Okun MS, Gwinn-Hardy K, Singleton AB (2006) The human prion gene M129V polymorphism is not associated with idiopathic Parkinson’s disease in three distinct populations. Neurosci Lett 395:227–229CrossRefPubMedGoogle Scholar
  62. 62.
    Simic G, Stanic G, Mladinov M, Jovanov-Milosevic N, Kostovic I, Hof PR (2009) Does Alzheimer’s disease begin in the brainstem? Neuropathol Appl Neurobiol 35:532–554CrossRefPubMedGoogle Scholar
  63. 63.
    Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H, Zilber N, Korczyn AD (2000) Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation. Ann Neurol 47:257–260CrossRefPubMedGoogle Scholar
  64. 64.
    Taratuto AL, Piccardo P, Reich EG, Chen SG, Sevlever G, Schultz M, Luzzi AA, Rugiero M, Abecasis G, Endelman M, Garcia AM, Capellari S, Xie Z, Lugaresi E, Gambetti P, Dlouhy SR, Ghetti B (2002) Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease. Neurology 58:362–367PubMedGoogle Scholar
  65. 65.
    Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, de Silva R, Lees A, Dickson DW (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 61:547–556PubMedGoogle Scholar
  66. 66.
    Vital A, Fernagut PO, Canron MH, Joux J, Bezard E, Martin-Negrier ML, Vital C, Tison F (2009) The nigrostriatal pathway in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 68:809–815CrossRefPubMedGoogle Scholar
  67. 67.
    Voogd J, Glickstein M (1998) The anatomy of the cerebellum. Trends Neurosci 21:370–375CrossRefPubMedGoogle Scholar
  68. 68.
    Wang XF, Dong CF, Zhang J, Wan YZ, Li F, Huang YX, Han L, Shan B, Gao C, Han J, Dong XP (2008) Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro. Mol Cell Biochem 310:49–55CrossRefPubMedGoogle Scholar
  69. 69.
    Zanusso G, Polo A, Farinazzo A, Nonno R, Cardone F, Di Bari M, Ferrari S, Principe S, Gelati M, Fasoli E, Fiorini M, Prelli F, Frangione B, Tridente G, Bentivoglio M, Giorgi A, Schinina ME, Maras B, Agrimi U, Rizzuto N, Pocchiari M, Monaco S (2007) Novel prion protein conformation and glycotype in Creutzfeldt-Jakob disease. Arch Neurol 64:595–599CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Gabor G. Kovacs
    • 1
    • 2
  • Jérémie Seguin
    • 3
  • Isabelle Quadrio
    • 3
  • Romana Höftberger
    • 1
  • István Kapás
    • 2
  • Nathalie Streichenberger
    • 3
  • Anne Gaëlle Biacabe
    • 4
  • David Meyronet
    • 3
  • Raf Sciot
    • 5
  • Rik Vandenberghe
    • 6
  • Katalin Majtenyi
    • 2
  • Lajos László
    • 7
  • Thomas Ströbel
    • 1
  • Herbert Budka
    • 1
  • Armand Perret-Liaudet
    • 3
  1. 1.Institute of NeurologyMedical University of Vienna, and Austrian Reference Center for Human Prion DiseasesViennaAustria
  2. 2.Neuropathology and Prion Disease Reference Center, Hungarian Reference Center for Human Prion DiseasesSemmelweis UniversityBudapestHungary
  3. 3.Prion Disease Laboratory, Pathology and Biochemistry, Groupement Hospitalier EstHospices Civils de Lyon/Claude Bernard UniversityLyonFrance
  4. 4.Agence Française de Sécurité Sanitaire des AlimentsˆLyon, Unité ATNCLyon Cedex 07France
  5. 5.Department of Pathology, University HospitalCatholic University of LeuvenLeuvenBelgium
  6. 6.Neurology DepartmentUniversity Hospital GasthuisbergLeuvenBelgium
  7. 7.Department of Anatomy, Cell and Developmental BiologyEotvos Lorand University of SciencesBudapestHungary

Personalised recommendations